Retatrutide Side Effects: What the Trial Record Says, and What It Does Not

Quick answer

As of September 2026, the peer-reviewed trial report most people quote for retatrutide side effects is the phase 2 obesity trial abstract, which names gastrointestinal events as the most common adverse events and reports increases in heart rate. Trials in type 2 diabetes have also been published, and as of September 22, 2026 none of the phase 3 records on ClinicalTrials.gov has posted results. Retatrutide (Eli Lilly's investigational compound LY3437943) is not FDA-approved, so there is no FDA-reviewed label and no FDA-reviewed list of its side effects: the openFDA label database and the Drugs@FDA database both return no record for it, while ClinicalTrials.gov lists 33 registered studies with retatrutide as the intervention. The "reta" vials sold online as research peptides sit outside that record entirely.

Why you keep seeing "side effects of reta" on social media

If your feed is full of people describing what "reta" did to them, you are not imagining it. Retatrutide has been in late-stage trials for several years, its early results were published in a major medical journal, and its nickname has migrated from trial forums to peptide storefronts, which is why searches for "reta peptide side effects" now sit next to searches for the drug's real name. The trouble is that the posts blend three different things: what trial participants experienced under medical supervision, what buyers of an unregulated product experienced, and what people expect based on other GLP-1 medicines.

This article separates those threads: what the public record documents, what it does not, the legal status of the substance sold online, and the medicines that do have FDA-approved labels today.

What is retatrutide?

The cleanest description comes from the abstract of the phase 2 obesity trial, published in the New England Journal of Medicine and indexed on PubMed (PubMed 37366315): "Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors." In plain language, it is a once-weekly injectable being studied because it acts on three hormone receptors at once: GIP, GLP-1 and glucagon. ClinicalTrials.gov calls it an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management.

That word, investigational, is the whole story: the compound is still being tested. For a refresher on the class itself, start with what a GLP-1 medication is.

What does the published trial record say about retatrutide side effects?

The peer-reviewed abstract most people are quoting, whether they know it or not, is the phase 2 obesity trial (ClinicalTrials.gov NCT04881760), published in 2023. It is not the only trial report: a phase 2 trial in type 2 diabetes (The Lancet, 2023, PubMed 37385280) and a phase 3 trial in type 2 diabetes, TRANSCEND-T2D-1 (The Lancet, June 2026, PubMed 42250575, ClinicalTrials.gov NCT06354660), are also published. This article quotes the obesity abstract; the diabetes reports are named so that nobody mistakes one abstract for the whole record. Its abstract reports on side effects in two sentences. The first begins: "The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity", and closes with a dosing detail this article does not reproduce. The second reports dose-dependent increases in heart rate that peaked during the trial and declined afterward.

That is the complete safety statement in the abstract. It names a category (gastrointestinal), a pattern (dose-related), a severity description (mostly mild to moderate), and one cardiovascular observation (heart rate). It does not name individual symptoms, it does not report long-term outcomes, and it summarizes a trial designed to find a dose range, not to characterize safety in a large population. That is why this article does not print a symptom list: the abstract does not contain one.

What matters is the shape of the evidence: one phase 2 abstract describing a controlled trial of adults with obesity, under physician supervision, with the trial drug supplied by the sponsor.

What is in the ClinicalTrials.gov registry?

ClinicalTrials.gov is the federal registry of clinical studies and the place to check status without relying on press coverage. A live query on September 22, 2026 for studies with retatrutide as the intervention returned a totalCount of 33. The registry lists 14 phase 3 studies: five Completed, eight Active, not recruiting, and one Recruiting. They cover obesity or overweight (NCT05929066, Completed), type 2 diabetes with obesity or overweight (NCT05929079, Completed), knee osteoarthritis (NCT05931367, Completed), cardiovascular disease (NCT05882045, Completed), three type 2 diabetes glycemic control studies (the TRANSCEND-T2D program, one Completed and two Active, not recruiting), cardiovascular and kidney outcomes (TRIUMPH-Outcomes, NCT06383390, Active, not recruiting), a head-to-head study against tirzepatide (NCT06662383, Active, not recruiting), maintenance of weight reduction (NCT06859268, Active, not recruiting), chronic low back pain (NCT07035093, Active, not recruiting), a liver disease master protocol (SYNERGY-Outcomes, NCT07165028, Recruiting), and two further obesity or overweight studies (NCT07232719 and NCT07357415, Active, not recruiting).

The entry for NCT05929066 states: "The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight." A registry entry describes design and status. It is not a results report, and completed status does not mean results are public.

The expanded access record

One record in the list is not a trial. NCT07629401 is titled "Pre-approval Expanded Access of Retatrutide (LY3437943)", sponsored by Eli Lilly and Company, with a status of Available. ClinicalTrials.gov prints it as single-patient expanded access for adults with severe obesity and at least two serious or life-threatening obesity-related complications who have not responded to approved therapy and are unable to participate in an ongoing clinical trial.

FDA's own explanation of the concept, sometimes called compassionate use, is that "expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product" outside of clinical trials when no comparable or satisfactory alternative is available. It is a case-by-case exception for a single patient, not a distribution channel.

What is not known?

• A phase 2 abstract is not a label. FDA-approved labels carry adverse reaction tables, warnings, contraindications and interaction sections reviewed by the agency. Retatrutide has none of that on the public record.
• Long-term data are limited. As of September 22, 2026, none of the 14 phase 3 records on ClinicalTrials.gov has a posted results section, and the phase 3 obesity studies are listed as completed or active without results.
• Rare events cannot be seen in a small trial. Uncommon side effects surface in large populations over time, which has not happened yet for this compound.
• Nothing in the trial record describes people who obtained the substance outside a trial. Every safety sentence above comes from supervised participants receiving sponsor-supplied drug.

Anyone who claims to know the full side effect profile of retatrutide is either reading unpublished data or guessing.

Why the "reta" sold online is not the study drug

This is the part social media skips. Products labeled reta or retatrutide are sold on peptide storefronts, usually with a "research use only" note on the listing. Here is what the law and the agency say about that.

First, FDA has addressed retatrutide by name. On its page about unapproved GLP-1 drugs used for weight loss, the agency states: "Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs." The same page notes that FDA has warned telehealth companies for marketing unapproved drugs such as retatrutide, including direct marketing to consumers, along with ingredient distributors and outsourcing facilities.

Second, the reason is structural, not a matter of agency preference. Under section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a), a pharmacy may compound only with bulk drug substances that comply with a USP or NF monograph, or, if no monograph exists, "are drug substances that are components of drugs approved by the Secretary", or appear on FDA's 503A bulks list. FDA's summary of the rule reads the same way: substances must comply with an applicable monograph, be "components of FDA-approved drug products if an applicable USP or NF monograph does not exist; or Appear on FDA's list of bulk drug substances that can be used in compounding (the 503A bulks list)". FDA's statement that retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law is that rule applied. Outsourcing facilities under section 503B operate under their own bulk substance conditions, and FDA's page lists outsourcing facilities among the parties it has warned over retatrutide. For what separates the two pharmacy types, see 503A vs 503B pharmacy. Compounded medications are not FDA-approved as final products.

Third, a research peptide listing is not a drug listing. FDA's compounding Q&A states the general principle: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." A product sold as a research chemical has not even entered that system: no regulator, monograph or pharmacy license stands behind the contents of the vial. Trial participants received a sponsor-manufactured drug under a protocol. A buyer receives whatever the listing describes.

The practical point: side effects reported by people who bought reta online cannot be attributed to retatrutide, because nobody outside the seller knows what the product contained. The same logic is why questions about whether compounded semaglutide is FDA-approved and whether compounded tirzepatide is safe matter even for medicines that do have approved versions.

What should you do if you are considering it?

Talk to a physician. Not a forum, not a seller, and not a telehealth ad, but a licensed physician who can look at your health history and the medicines you already take. Bring the questions in the last section.

If you want access to an investigational drug, the legitimate route is a registered clinical trial. ClinicalTrials.gov lists every registered study, its status and its eligibility criteria, and enrollment goes through the study site, not a storefront. Participants are monitored, receive sponsor-manufactured drug, and contribute to the very safety record that is missing today.

Which weight-management medicines are FDA-approved today?

While retatrutide remains investigational, three medicines carry FDA-approved labels for chronic weight management in adults as of September 2026. The wording below comes from each label's Indications and Usage section, read through openFDA. Each is indicated in combination with a reduced-calorie diet and increased physical activity. This is a list, not a ranking.

• Wegovy (semaglutide) injection: indicated "to reduce excess body weight and maintain weight reduction long term" in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. The label also lists cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, and a liver indication (MASH) in adults.
• Zepbound (tirzepatide) injection: indicated "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition", and to treat moderate to severe obstructive sleep apnea in adults with obesity.
• Foundayo (orforglipron) tablets: indicated "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition." A separate article covers orforglipron side effects as the label lists them.

Each label carries a boxed warning about the risk of thyroid C-cell tumors. Whether any of these is appropriate for a particular person is a decision for a licensed physician working from the label and the patient's history. If you are handed a prescription, how to read a prescription label explains what each line means.

Questions to bring to a physician

• Is there an FDA-approved medicine whose label fits my situation, and what does its adverse reactions section say?
• Given my history (thyroid, pancreas, gallbladder, kidney, heart rhythm, pregnancy plans), which warnings in that label apply to me?
• If I am interested in an investigational medicine, is there a registered clinical trial I could be screened for, and what would participation involve?
• I have seen products sold online as reta. What do you want me to know about them?

A physician who answers from the label and the registry, rather than from a forum, is holding to the same evidence standard this article tried to keep.

This article is for informational purposes only and does not constitute medical advice. Medication is prescribed only if a licensed physician determines it is appropriate. Retatrutide is an investigational compound with no FDA-approved label; nothing here describes how to obtain it or recommends its use outside a registered clinical trial.